Treatment of Patients with HER2-Positive Disease

Have you used adjuvant trastuzumab?

If yes, in approximately how many patients have you used adjuvant trastuzumab before and after the 2005 ASCO meeting?

In approximately how many patients have you stopped using adjuvant trastuzumab because of a decrease in EF or other cardiac concerns?

Have you used adjuvant trastuzumab without chemotherapy?

Have you utilized dose-dense AC

paclitaxel/trastuzumab in a nonprotocol setting?

Have you used TCH as nonprotocol adjuvant therapy in patients with HER2-positive tumors?

A 60-year-old woman was diagnosed three years earlier with node-positive, ER-positive, PR-positive, HER2-positive breast cancer and received AC

paclitaxel, trastuzumab and anastrozole. While receiving anastrozole, she now has moderately symptomatic bone metastases and no other sites of disease on staging. Which therapy would you recommend to this patient?

A 60-year-old woman was diagnosed three years earlier with node-positive, ER-negative, PR-negative, HER2-positive breast cancer and received AC

paclitaxel and trastuzumab. She now has moderately symptomatic bone metastases and no other sites of disease on staging. Which therapy would you recommend to this patient?

Continued from previous case

Continued from previous case

Continued from previous case

Continued from previous case

Cost and reimbursement issues aside and assuming lapatinib were available for clinical use, how would you generally treat a patient with ER-negative, HER2-positive breast cancer who developed metastatic disease nine months after completing one year of adjuvant therapy with AC

paclitaxel/trastuzumab?